FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to biotechnology. There are presented versions of human or macaque anti-Bv8 antibodies, each of which is characterised by the fact that it contains 6 CDR. What is described is a coding nucleic acid; a based expression vector for producing the antibody; a host cell for expressing the vector-based antibodies, as well as a method for producing the antibody with using the cell. There are disclosed a pharmaceutical composition using the antibody in an effective amount, as well as using the antibody for treating tumour, cancer or disturbed cell proliferation. What is presented is using the antibody for reducing or inhibiting angiogenesis in an individual, as well as for inhibiting endothelial cell proliferation.
EFFECT: using the invention provides the human or macaque Bv8 affine antibodies (KD) of less than 10-11 M as measured by BIACORE 3000 technique, which can find application in therapy of various cancer diseases.
25 cl, 43 dwg, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANGIOGENESIS INHIBITION | 2008 |
|
RU2471498C2 |
| ANTIBODIES AGAINST AXL AND THEIR APPLICATION | 2011 |
|
RU2577986C2 |
| ANTIBODIES AND IMMUNOCONJUGATES AND THEIR APPLICATION | 2007 |
|
RU2436796C9 |
| NRR Notch1 ANTIBODIES AND METHODS OF APPLICATION THEREOF | 2008 |
|
RU2476443C2 |
| ANTIBODIES AGAINST FGFR3 AND METHODS OF THEIR APPLICATION | 2010 |
|
RU2568066C2 |
| METHODS OF TREATING CANCER USING PD-1 AXIS BINDING AND VEGF ANTAGONISTS | 2013 |
|
RU2689760C2 |
| NOVEL ANTIBODIES | 2008 |
|
RU2490277C2 |
| ANTIBODIES AGAINST NEYROPILIN AND METHODS OF THEIR APPLICATION | 2011 |
|
RU2571226C2 |
| ANTI-EphB4 ANTIBODIES AND METHODS OF USING SAID ANTIBODIES | 2007 |
|
RU2450020C2 |
| ANTI-LRP6 ANTIBODIES | 2011 |
|
RU2587625C2 |
